Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $5.6 million.

  • Axsome Therapeutics' Non-cash Items rose 1099.11% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 1099.11%. This contributed to the annual value of $5.4 million for FY2024, which is 9668.61% down from last year.
  • As of Q3 2025, Axsome Therapeutics' Non-cash Items stood at $5.6 million, which was up 1099.11% from $5.6 million recorded in Q2 2025.
  • Axsome Therapeutics' Non-cash Items' 5-year high stood at $318.3 million during Q1 2024, with a 5-year trough of $3.2 million in Q3 2022.
  • Moreover, its 4-year median value for Non-cash Items was $5.6 million (2025), whereas its average is $78.8 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 456749.43% in 2023, then plummeted by 9669.52% in 2024.
  • Axsome Therapeutics' Non-cash Items (Quarter) stood at $3.5 million in 2022, then soared by 4567.49% to $162.0 million in 2023, then tumbled by 96.69% to $5.4 million in 2024, then rose by 3.42% to $5.6 million in 2025.
  • Its Non-cash Items stands at $5.6 million for Q3 2025, versus $5.6 million for Q2 2025 and $148.8 million for Q1 2025.